Immunological Changes of Basophil Hyperreactivity to Sweat in Patients With Well-Controlled Atopic Dermatitis.
IgE
MGL_1304
Malassezia
atopic dermatitis
basophil
dupilumab
histamine release
sweat antigen
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
02
2022
accepted:
23
05
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Sweat aggravates atopic dermatitis (AD). In patients with AD, type-I hypersensitivity to sweat may be shown by histamine release from patients' basophils in response to the semi-purified sweat antigen (QR), and the presence of specific immunoglobulin E (IgE) binding to MGL_1304, the component of QR. However, there has been no information on the immunological changes of type-I hypersensitivity to the sweat antigen in patients with well-controlled AD using topical corticosteroids (TCSs) and/or biologics as treatments. Histamine-releasing tests using patients' basophils and QR and the detection of serum IgE against MGL_1304 and mite allergen Der f 1 were performed in patients with AD who were well controlled by topical TCS with/without dupilumab for 53-96 weeks. In total, 14 patients were enrolled. Seven patients received TCS therapy alone (TCS group), and seven patients received TCS with dupilumab therapy (dupilumab group). In all participants, the level of specific IgE against MGL_1304 decreased after treatments, but histamine release from basophils in response to QR did not show a statistically significant reduction; rather, it increased. In the dupilumab group, all changes in histamine release induced by QR (increase), the IgE level against MGL_1304 (decrease), and that against Der f 1 (decrease) were statistically significant, whereas the TCS group showed no significant change in any of them. The well-controlled condition for 53-96 weeks resulted in no reduction of the hyperreactivity of basophils against in patients with AD, even with the treatment with dupilumab. This study suggests persistent basophil hyperreactivity to sweat antigen over a year or longer.
Sections du résumé
Background
Sweat aggravates atopic dermatitis (AD). In patients with AD, type-I hypersensitivity to sweat may be shown by histamine release from patients' basophils in response to the semi-purified sweat antigen (QR), and the presence of specific immunoglobulin E (IgE) binding to MGL_1304, the component of QR. However, there has been no information on the immunological changes of type-I hypersensitivity to the sweat antigen in patients with well-controlled AD using topical corticosteroids (TCSs) and/or biologics as treatments.
Method
Histamine-releasing tests using patients' basophils and QR and the detection of serum IgE against MGL_1304 and mite allergen Der f 1 were performed in patients with AD who were well controlled by topical TCS with/without dupilumab for 53-96 weeks.
Results
In total, 14 patients were enrolled. Seven patients received TCS therapy alone (TCS group), and seven patients received TCS with dupilumab therapy (dupilumab group). In all participants, the level of specific IgE against MGL_1304 decreased after treatments, but histamine release from basophils in response to QR did not show a statistically significant reduction; rather, it increased. In the dupilumab group, all changes in histamine release induced by QR (increase), the IgE level against MGL_1304 (decrease), and that against Der f 1 (decrease) were statistically significant, whereas the TCS group showed no significant change in any of them.
Conclusion
The well-controlled condition for 53-96 weeks resulted in no reduction of the hyperreactivity of basophils against in patients with AD, even with the treatment with dupilumab. This study suggests persistent basophil hyperreactivity to sweat antigen over a year or longer.
Identifiants
pubmed: 35844573
doi: 10.3389/fimmu.2022.883605
pmc: PMC9277351
doi:
Substances chimiques
Antigens
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
883605Informations de copyright
Copyright © 2022 Numata, Takahagi, Ishii, Morioke, Kan, Mizuno, Yanase, Kawaguchi, Tanaka and Hide.
Déclaration de conflit d'intérêts
TN has received a research grant from Sun pharma and Kyowa-Kirin. ST has received a research grant from Sanofi, Maruho, and Taiho Pharma and an honorarium from Novartis. MH has received a research grant from GlaxoSmithKline, Kaken Pharmaceutical, Mitsubishi-Tanabe, Novartis, Sanofi, and Taiho Pharma, honorarium from Ely-Lilly, Kaken-Pharmaceutical, Kyowa-Kirin, Mitsubishi-Tanabe, MSD, Novartis, Sanofi, Taiho Pharma, Teikoku seiyaku, and Uriach. AT has received a research grant from Maruho, Sanofi, Eisai, and Mitsubishi Tanabe Pharma and an honorarium from Maruho, Torii Pharma, Mitsubishi Tanabe Pharma, Sanofi, and Taiho Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 1980 Aug;125(2):701-10
pubmed: 7391576
Acta Derm Venereol. 2002;82(5):335-40
pubmed: 12430731
J Allergy Clin Immunol. 2013 Sep;132(3):608-615.e4
pubmed: 23726042
Allergol Int. 2018 Oct;67(4):435-441
pubmed: 30075993
Exp Dermatol. 2006 Apr;15(4):283-90
pubmed: 16512875
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):99-104
pubmed: 26541454
N Engl J Med. 1993 Jun 3;328(22):1599-604
pubmed: 7683772
J Allergy Clin Immunol. 2012 Dec;130(6):1344-54
pubmed: 22951056
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
Allergol Int. 2020 Jul;69(3):356-369
pubmed: 32265116
Allergol Int. 2016 Jan;65(1):109-11
pubmed: 26666491
Allergol Int. 2021 Jul;70(3):327-334
pubmed: 33674191
J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300
pubmed: 25482871
Pediatr Dermatol. 2009 Mar-Apr;26(2):223-5
pubmed: 19419481
Br J Dermatol. 2004 Jun;150(6):1154-61
pubmed: 15214903
Eur J Dermatol. 2010 May-Jun;20(3):410-1
pubmed: 20413368
Br J Dermatol. 2009 Feb;160(2):426-8
pubmed: 18811685
Acta Derm Venereol Suppl (Stockh). 1989;144:83-7
pubmed: 2800911
J Dermatol Sci. 2013 Apr;70(1):3-11
pubmed: 23473856
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36
pubmed: 29471919
Allergol Int. 2014 Mar;63(1):83-93
pubmed: 24457815
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242